作者: Bora, Girdhar ; Mittal, Ankur ; Trivedi, Sameer ; Kumar, Niraj ; Sinha, Sanjay ; Nayyar, Rishi ; Elhence, Anil ; Jose, Sujith ; Mandal, Swarnendu ; Patel, Anita ; Vasudeva, Pawan ; Singh, Harprit ; Kumar, Vikas ; Bansal, Harbans ; Madduri, Vijay Kumar Sarma ; Nelivigi, Girish G

ABSTRACTIntroduction:A study was performed to determine the most common and most bothersome symptoms and clinical associations in young men (18–40 years) presenting with lower urinary tract symptoms (LUTS).Methods:Cross-sectional study was conducted across 16 centers. Urinary symptoms, impact of bladder problems, bowel symptoms, erectile dysfunction, premature ejaculation, bladder pain, non-bladder myofascial pain, and general well-being were assessed by validated questionnaires.Results:A total of 448 men (median age 30 years) were included. Nocturia ≥1 (89.1%) and feeling of incomplete bladder evacuation (76.6%) were the most common symptoms while the most bothersome symptoms were daytime frequency and nocturia (median score 5; interquartile range 2–8, for both) on the International Consultation on Incontinence Questionnaire for Male LUTS questionnaire. Bladder symptoms were associated with severe or many severe problems (response 5 or 6, on the Patient Perception of Bladder Conditions Questionnaire) in 17.8% of the patients. Men between 18 and 20 years reported greater bother with their bladder condition. Normal erections and “very good” control over ejaculation were reported by 49.8% and 15.6%, respectively. Constipation and loose stools were reported by 22.8% and 12.9%, while bladder pain and non-bladder myofascial pain were reported by 72.5%, and 48.2%, respectively. 17.0% of the patients reported low scores on the WHO-5 Well-Being Scale. Two distinct patient clusters were identified. A larger cluster (63.9%) that presented with voiding symptoms and urgency but fewer sexual or pain symptoms, and a smaller cluster that showed pronounced sexual symptoms, pain, daytime frequency, and nocturia.Conclusions:The most common urinary symptoms in young men are nocturia and a sense of incomplete evacuation. Daytime frequency and nocturia are the most bothersome symptoms. It is important to assess associated symptoms in young men presenting with LUTS.

2025-01-22·Journal of Crohn's and Colitis

P1048 Vedolizumab in Indian patients with Inflammatory Bowel Disease: Final results from a prospective, multicentre, open-label, phase 4 study

作者: Bhardwaj, V ; Banerjee, R ; Sood, A ; Ahuja, V ; Kabrawala, M ; Arora, S ; Ramesh Kumar, B ; Anumula, K ; Dalal, A ; Mukewar, S ; Mohan Prasad, V G ; Bahuguna, G

AbstractBackgroundIndia has rising prevalence of Inflammatory Bowel Disease (IBD), with an estimated 1.4 million cases reported in 2010.¹ Vedolizumab (VDZ) has demonstrated safety and effectiveness internationally as an alternative for achieving clinical response and remission. 2,3 There is limited data on VDZ’s efficacy and safety for Indian patients. This study provides the first focused evaluation of VDZ in this population.MethodsIn this prospective, multicenter, open-label phase IV study (NCT04804540), patients aged 18–65 with moderate to severe ulcerative colitis (UC) or Crohn’s disease (CD) unresponsive to corticosteroids, immunomodulators or anti-TNF agents received VDZ 300 mg intravenously at weeks 0, 2, and 6 (induction) and at weeks 14, 22, 30, 38, and 46 (maintenance).Patients had diagnosis of moderate to severe active UC or CD with a Full Mayo Score of 6-12 for UC and Harvey Bradshaw Index (HBI) of ≥8 for CD at the time of enrollment. Clinical remission was defined as Simple Clinical Colitis Activity (SCCAI) ≤2 for UC or HBI ≤4 for CD, while clinical response was defined as an SCCAI decrease of ≥3 or physician assessed response for UC and HBI decrease of ≥3 for CD.The primary objective analyzed the safety of VDZ in Indian UC or CD patients, with a secondary objective of assessing efficacy. The final analysis included data up to Week 46 or patient discontinuation.ResultsOf 215 patients screened, 150 were enrolled (102 with UC: median age 39 years; 48 with CD: median age 31 years). The median treatment duration was 325 days for UC and 323 for CD. AEs affected 83 patients (55.3%), with mild AEs in 72 (48%). TEAEs occurred in 52 (51%) patients with UC and 29 (60.4%) with CD, while SAEs occurred in 8 (5.3%) patients, with 2 treatment- related. Additionally, 5 patients (3.3%) had at least 1 ADR, and 4 (2.7%) had AESI. Reported ADR/AESI cases included one patient each with pulmonary tuberculosis, tuberculous pleurisy, rectal adenocarcinoma, and hypertension. Anaemia was most common TEAE, and small intestinal obstruction was most frequent SAE. No AE related deaths occurred(Table 1). Overall clinical response rates were 60.7% at Week 14, 65.3% at Week 30, and 72% at Week 46. Remission rates were 42% at Week 14, 44% at Week 30, and 53.3% at Week 46(Fig 1). Mucosal healing was observed in 27/150 (18%) patients at week 46. Quality of life scores showed improvements across both UC and CD groups, with median Short Inflammatory Bowel Disease Questionnaire score increases noted from baseline of 5 at week 14 to 13 at week 46 in both groups.ConclusionThis study demonstrates that vedolizumab has a good safety profile in Indian patients with moderate-to-severe UC and CD, offering well-tolerated option for achieving clinical response and remission.References1.Singh P, Ananthakrishnan A, Ahuja V. Pivot to Asia: inflammatory bowel disease burden. Intest Res. 2017 Jan;15(1):138-141. doi: 10.5217/ir.2017.15.1.1382.Ooi CJ, Hilmi IN, Kim HJ, et al. Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study. Intest Res. 2021;19(1):71-82. doi:10.5217/ir.2019.09159.3.Singh H, Grewal N, Arora E, Kumar H, Kakkar AK. Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease. J Nat Sci Biol Med. 2016;7(1):4-9. doi:10.4103/0976-9668.175016.

2025-01-14·Cureus

A Cross-Sectional Study Comparing Patient Education Guides Created by ChatGPT and Google Gemini for Common Cardiovascular-Related Conditions

Article

作者: George, Collin R ; Menon, Gayatri Anilkumar ; Varsaale, Nayanaa ; K, Saswaath Thiruvengadam ; Saravanan, Hariharasudhan ; Gunturi, Lakshmi Manasa

Introduction Obesity, hypertension, and hypertriglyceridemia are key components of metabolic syndrome, a major contributor to cardiovascular diseases (CVDs), which remain a leading cause of global mortality. Patient education on these conditions can empower individuals to adopt preventive measures and manage risks effectively. This study compares ChatGPT and Google Gemini, two prominent artificial intelligence (AI) tools, to evaluate their utility in creating patient education guides. ChatGPT is known for its conversational depth, while Google Gemini emphasizes advanced natural language processing. By analyzing readability, reliability, and content characteristics, the study highlights how these AI tools cater to diverse patient needs, aiming to enhance health literacy outcomes. Methodology A cross-sectional study evaluated patient education guides on obesity, hypertension, and hypertriglyceridemia, focusing on their links to metabolic syndrome. Responses from ChatGPT and Google Gemini were analyzed for word count, sentence count, readability (using the Flesch-Kincaid calculator), similarity score (using Quillbot), and reliability score (using the modified DISCERN score), with statistical analyses performed using the R Version 4.3.2. Results Statistical analysis revealed a significant difference in word and sentence counts between the AI tools: ChatGPT averaged 591.50 words and 66 sentences, while Google Gemini had 351.50 words and 36 sentences (p = 0.001 and p < 0.0001). However, the average words per sentence, average syllables per word, grade level, similarity percentage, and reliability scores did not differ significantly. Although Google Gemini had a higher ease score (41.75) compared to ChatGPT (34.10), this difference was not statistically significant (p = 0.080). Both tools exhibited similar readability and reliability, indicating their effectiveness for patient education, despite ChatGPT providing longer responses. Conclusion The study found no significant difference between the two AI tools in terms of ease, grade, and reliability scores, with no correlation between ease and reliability scores.

100 项与 Government General Hospital 相关的药物交易

登录后查看更多信息

100 项与 Government General Hospital 相关的转化医学

登录后查看更多信息